|
Neurodermatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results indicated that B7-H3 is abnormally expressed in LSC skin tissue and positively regulates LC expansion.
|
31056761 |
2020 |
|
Lichen Simplex Chronicus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results indicated that B7-H3 is abnormally expressed in LSC skin tissue and positively regulates LC expansion.
|
31056761 |
2020 |
|
Brain Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
|
30655315 |
2019 |
|
Noninfiltrating Intraductal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High B7-H3 and B7-H4 expression was observed in 58 (73.4%) and 62 (78.5%) cases with DCIS, respectively.
|
31714284 |
2019 |
|
Merkel cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that colocalized expression of B7-H3/CD31 is a poor prognostic indicator and suggest therapies targeting B7-H3 may represent an effective approach to augmenting immune-activating therapies for MCC.
|
30808776 |
2019 |
|
CNS disorder
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Patients with CNS disease expressing the antibody target antigen B7-H3 were eligible.
|
30879172 |
2019 |
|
Chondrosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
4 studies investigated B7-H3 expression in osteosarcoma, but there is no study on B7-H3 expression in chondrosarcoma.
|
31060912 |
2019 |
|
Chordoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
One study reported B7-H3 expression in osteoclastomas and one study investigated B7-H3 expression in chordoma tumor tissues.
|
31060912 |
2019 |
|
Choriocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PD-L1, B7-H3 and VISTA levels were significantly higher in choriocarcinomas and PSTTs than in ETTs.
|
31013360 |
2019 |
|
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients with higher levels if B7-H3 had significantly higher risk for mortality in the 5-year follow-up compared with the lower group, logic analysis was also conducted and results showed that B7-H3 might be an independent risk factor for 5-year mortality for CHD patients.
|
30328478 |
2019 |
|
Craniopharyngioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results revealed B7-H3 was highly expressed in CPs and targeting B7-H3 might therefore be an effective therapeutic strategy against craniopharyngioma.
|
31043272 |
2019 |
|
Glomerulonephritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Mice deficient of B7-H3 or treated with a B7-H3 specific antibody produced significantly higher levels of anti-DNA autoantibodies and more severe glomerulonephritis than wild-type mice, indicating an inhibitory function of B7-H3 in this model.
|
31113935 |
2019 |
|
Graft-vs-Host Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Haplo-HSCT patients with higher + 7 days B7H1/B7H3 or + 28 days ST2 serum levels had poor GVHD-related mortality (GRM) (B7H1: P < 0.001; B7H3: P = 0.002; ST2: P = 0.047).
|
30725359 |
2019 |
|
Lupus Vulgaris
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we analyzed the serum expression of B7-H3 in 113 rheumatoid arthritis and systemic lupus erythematous patients using the ELISA and found a positive correlation between B7-H3 and VEGF.
|
31292886 |
2019 |
|
Lupus Erythematosus, Discoid
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we analyzed the serum expression of B7-H3 in 113 rheumatoid arthritis and systemic lupus erythematous patients using the ELISA and found a positive correlation between B7-H3 and VEGF.
|
31292886 |
2019 |
|
Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study highlights B7-H3 as a viable target in MB angiogenesis, and that the expression of miR-29 can inhibit B7-H3 and sensitize MB cells to treatment with MYC-inhibiting drugs.
|
31382461 |
2019 |
|
Paget Disease Extramammary
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These findings provide an initial characterization of EMPD tumor cell expression of B7-H3, B7-H4, PD-L1, PD-L2, MAGE-A, and NY-ESO-1 and indicate the potential for new immunotherapeutic options for patients with EMPD.
|
31692889 |
2019 |
|
Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, ST2 deficiency diminished the bleomycin-induced B7H3 and IL-13 upregulation, suggesting a role for type 2 innate lymphoid cells.<b>Conclusions:</b> Pulmonary fibrosis caused significant alterations in BM with expansion and activation of monocytic cells, which enhanced fibrosis when transplanted to naive recipients with potential mediation by a novel role for B7H3 in the pathophysiology of pulmonary fibrosis in both mice and humans.
|
31106564 |
2019 |
|
Small cell carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
PD-L1 protein was detected in 7.3%, B7-H3 in 64.9% and B7-H4 in 2.6% of SCLC cases.
|
30850021 |
2019 |
|
Primary Sjögren's syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, this study aimed to investigate the role and mechanism of B7-H3 in HSGE cells in pSS.
|
31412888 |
2019 |
|
Congenital heart disease
|
0.010 |
Biomarker
|
group |
BEFREE |
The aim of this study was to investigate the role of B7-H3 in prognosis of congenital heart disease (CHD) children patients.
|
30328478 |
2019 |
|
Giant Cell Tumor of Bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
One study reported B7-H3 expression in osteoclastomas and one study investigated B7-H3 expression in chordoma tumor tissues.
|
31060912 |
2019 |
|
Trophoblastic Tumor, Placental Site
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PD-L1, B7-H3 and VISTA levels were significantly higher in choriocarcinomas and PSTTs than in ETTs.
|
31013360 |
2019 |
|
Childhood Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study highlights B7-H3 as a viable target in MB angiogenesis, and that the expression of miR-29 can inhibit B7-H3 and sensitize MB cells to treatment with MYC-inhibiting drugs.
|
31382461 |
2019 |
|
Childhood Craniopharyngioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results revealed B7-H3 was highly expressed in CPs and targeting B7-H3 might therefore be an effective therapeutic strategy against craniopharyngioma.
|
31043272 |
2019 |